Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EPS (Weighted Average and Diluted) (2022 - 2025)

Envoy Medical's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.34 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 7.93% year-over-year to -$0.34; the TTM value through Sep 2025 reached -$0.34, down 79.3%, while the annual FY2024 figure was -$1.07, 55.12% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.34 at Envoy Medical, down from -$0.33 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.23 in Q1 2022 and bottomed at -$1.13 in Q4 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.26 (2024), against an average of -$0.2.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 200.0% in 2023 before it crashed 2143.01% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.13 in 2022, then soared by 107.08% to $0.08 in 2023, then plummeted by 428.16% to -$0.26 in 2024, then fell by 29.76% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for COCH's EPS (Weighted Average and Diluted) are -$0.34 (Q3 2025), -$0.33 (Q2 2025), and -$0.29 (Q1 2025).